AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29312993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical wound pain
Number of subjects: 84
Study 29312993 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical wound pain
Number of subjects: 84
Study 29312993 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 removal procedure
Number of subjects: 84
Study 26170622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 210
Study 26170622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 210
Study 23842215 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (12.5 mg 3 times/d; over 3 d)
Number of subjects: 50
Study 23842215 — intervention group
Group type: COMPARATOR
Intervention: Albumin (8 g/L of removed ascites)
Number of subjects: 50
Study 22468094 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus, basiliximab, and mycophenolate mofetil with steroid withdrawal
Number of subjects: 30
Study 22468094 — intervention group
Group type: COMPARATOR
Intervention: steroid treatment (control group)
Number of subjects: 30
Study 19242829 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and Levamisole (Lev)
Number of subjects: 425
Study 19242829 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 425
Study 17446248 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Watch program
Number of subjects: 459
Study 15382102 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandage
Number of subjects: 387
Study 15382102 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch bandage
Number of subjects: 387
Study 11451595 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with Polymyxin E, Tobramycin, and Amphotericin B
Number of subjects: 23
Study 11451595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9677847 — intervention group
Group type: EXPERIMENTAL
Intervention: AO osteosynthesis (A group)
Number of subjects: 219
Study 9677847 — intervention group
Group type: COMPARATOR
Intervention: External fixator (B group)
Number of subjects: 219
Study 8295321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (10 mg/d)
Number of subjects: 26
Study 8295321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8295321 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL turnover study
Number of subjects: 26
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (blood concentration of approximately 0.08%)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (white light)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (green light)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (red light)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (blue light)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (short interval of 40 min)
Number of subjects: 0
Study 3068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (long interval of 60 min)
Number of subjects: 0
Study 3068596 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study 30130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Control impairment (CI) in sagittal plane
Number of subjects: 24
Study 30130429 — intervention group
Group type: COMPARATOR
Intervention: No control impairment (CI) in sagittal plane
Number of subjects: 24
Study 30681515 — intervention group
Group type: EXPERIMENTAL
Intervention: S3/30-CXL
Number of subjects: 93
Study 30681515 — intervention group
Group type: EXPERIMENTAL
Intervention: A9/10-CXL
Number of subjects: 93
Study 30681515 — intervention group
Group type: EXPERIMENTAL
Intervention: A30/4-CXL
Number of subjects: 93
Study 25476448 — intervention group
Group type: EXPERIMENTAL
Intervention: HT7 verum acupuncture
Number of subjects: 120
Study 25476448 — intervention group
Group type: COMPARATOR
Intervention: HT7 non‐penetrating sham acupuncture
Number of subjects: 120
Study 25476448 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at a sham point
Number of subjects: 120
Study 25476448 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 120
Study 23490655 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy (n=117)
Number of subjects: 647
Study 23490655 — intervention group
Group type: COMPARATOR
Intervention: Observation (n=125)
Number of subjects: 647
Study 23490655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-uPA/PAI-1 patients
Number of subjects: 647
Study 23490655 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy (per-protocol analysis)
Number of subjects: 647
Study 21185977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program (six weekly interactive lessons based on the Theory of Planned Behavior)
Number of subjects: 141
Study 21185977 — intervention group
Group type: COMPARATOR
Intervention: Control group (six weekly nonrelated financial lessons by mail)
Number of subjects: 141
Study 18559141 — intervention group
Group type: COMPARATOR
Intervention: Self-regulation training for kindergarten teachers
Number of subjects: 132
Study 17578321 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal decoctions (Shitong mixture No. 1 before laparoscopic cholecystectomy, Liujunzi decoction after laparoscopic cholecystectomy for three days)
Number of subjects: 360
Study 17578321 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine and placebo
Number of subjects: 360
Study 15489577 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered as three intravenous infusions
Number of subjects: 13
Study 15489577 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisolone (1.5 mg/kg daily for 2 weeks, followed by 1 mg/kg for 1 week, then weekly reduction of 5 mg)
Number of subjects: 13
Study 11597530 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg GTN patches
Number of subjects: 50
Study 11597530 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 50
Study 9699139 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) regimens (PTA, PCA)
Number of subjects: 0
Study 9699139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8040999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised solutions of saliva
Number of subjects: 15
Study 8040999 — intervention group
Group type: COMPARATOR
Intervention: Nebulised solutions of isotonic saline
Number of subjects: 15
Study 3141188 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nitroglycerin paste (10 mg)
Number of subjects: 10
Study 3141188 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin ointment (5 mg)
Number of subjects: 10
Study 29110615 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-water (300 mL per day)
Number of subjects: 73
Study 29110615 — intervention group
Group type: COMPARATOR
Intervention: Placebo water (control group)
Number of subjects: 73
Study 28709081 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with contingency management incentives for treatment attendance (CM-Att; n=30)
Number of subjects: 100
Study 28709081 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with contingency management for each day of no drinking per SCRAMx (CM-Abst; n=17)
Number of subjects: 100
Study 28709081 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=36)
Number of subjects: 100
Study 28709081 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=17)
Number of subjects: 100
Study 26183437 — intervention group
Group type: EXPERIMENTAL
Intervention: Travalert dosing aid
Number of subjects: 208
Study 26183437 — intervention group
Group type: EXPERIMENTAL
Intervention: Morisky Measure of Adherence Scale
Number of subjects: 208
Study 26183437 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of Missed Dose self-report measures
Number of subjects: 208
Study 26183437 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication possession ratio
Number of subjects: 208
Study 23918028 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intravenous infusion
Number of subjects: 60
Study 23918028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 21225321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active or passive relaxation exercises
Number of subjects: 39
Study 18793578 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (dosing details not specified)
Number of subjects: 15
Study 18793578 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for quantification of remifentanil
Number of subjects: 15
Study 18793578 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 15
Study 16414395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pale sulfonated shale oil (PSSO) 10% applied daily for 20 weeks
Number of subjects: 119
Study 16414395 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 119
Study 16414395 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSO
Number of subjects: 119
Study 15282660 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant platelet factor 4 (rPF4) at doses of 0.5, 1.0, 2.5, or 5.0 mg/kg
Number of subjects: 0
Study 15282660 — intervention group
Group type: COMPARATOR
Intervention: Protamine
Number of subjects: 0
Study 11523384 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTs derived from systematic reviews and meta-analyses
Number of subjects: 0
Study 11523384 — intervention group
Group type: COMPARATOR
Intervention: Pooled absolute risk differences in meta-analyses
Number of subjects: 0
Study 11523384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled relative risk reductions
Number of subjects: 0
Study 9740864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg/d
Number of subjects: 41
Study 9740864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9740864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 41
Study 8376914 — intervention group
Group type: EXPERIMENTAL
Intervention: ridogrel 300 mg b.i.d.
Number of subjects: 27
Study 8376914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ridogrel 300 mg b.i.d. and ketanserin 20 mg t.i.d.
Number of subjects: 27
Study 8376914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8376914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ridogrel and ketanserin during 3-month follow-up
Number of subjects: 27
Study 3769491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous, symmetric, bihemifield stimuli (SSBS)
Number of subjects: 0
Study 28750153 — intervention group
Group type: EXPERIMENTAL
Intervention: 595-nm Pulsed-Dye Laser (PDL)
Number of subjects: 61
Study 28750153 — intervention group
Group type: COMPARATOR
Intervention: 595-nm Pulsed-Dye Laser (PDL) + 1064-nm Nd:YAG (DWL)
Number of subjects: 61
Study 26711164 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255
Study 26711164 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 255
Study 26711164 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 255
Study 26711164 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and health education
Number of subjects: 255
Study 24930649 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-101 breath detection monitor
Number of subjects: 101
Study 24930649 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 101
Study 22956204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine wound infusion (0.5%)
Number of subjects: 48
Study 22956204 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 48
Study 20818902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood-pressure control
Number of subjects: 1094
Study 20818902 — intervention group
Group type: COMPARATOR
Intervention: Standard blood-pressure control
Number of subjects: 1094
Study 18544469 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta9‐THC
Number of subjects: 20
Study 18544469 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta9‐THC and CBD
Number of subjects: 20
Study 18544469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 20
Study 15660547 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft music (six 45‐minute sedative music tapes) for 3 weeks
Number of subjects: 60
Study 12689884 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 120
Study 12689884 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 120
Study 10735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 200 mg b.d. (RABF)
Number of subjects: 106
Study 10735922 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg b.d. (RABM)
Number of subjects: 106
Study 8960592 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day of oral ascorbic acid
Number of subjects: 50
Study 8960592 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 50
Study 1305155 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 40
Study 1305155 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing alone
Number of subjects: 40
Study 1305155 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing in conjunction with citric acid treatment
Number of subjects: 40
Study 1305155 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 40
Study 1305155 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 nondiseased, untreated teeth)
Number of subjects: 40
Study 3895033 — intervention group
Group type: EXPERIMENTAL
Intervention: mesulergine (mean dosage, 27.4 mg/d)
Number of subjects: 20
Study 3895033 — intervention group
Group type: COMPARATOR
Intervention: bromocriptine (mean dosage, 40.8 mg/d)
Number of subjects: 20
Study 29975283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined circuit exercise (60 min/day, 3 days/week for 12 weeks)
Number of subjects: 24
Study 29975283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined circuit exercise
Number of subjects: 24
Study 27450487 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+ozone
Number of subjects: 60
Study 27450487 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 60
Study 24673474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine and Hydroxyzine
Number of subjects: 92
Study 24673474 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine, Levocetirizine, and Rupatadine
Number of subjects: 92
Study 24673474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheniramine and Rupatadine
Number of subjects: 92
Study 24673474 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Antihistamines
Number of subjects: 92
Study 24673474 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation Antihistamines
Number of subjects: 92
Study 24673474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupadatine and Pheniramine
Number of subjects: 92
Study 22925074 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed extract (1 g/day, containing at least 100 mg of SDG)
Number of subjects: 90
Study 22925074 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed meal (90 g/day, containing at least 270 mg of SDG)
Number of subjects: 90
Study 22925074 — intervention group
Group type: COMPARATOR
Intervention: Collagen (1 g/day, placebo group)
Number of subjects: 90
Study 20116706 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis
Number of subjects: 150
Study 20116706 — intervention group
Group type: COMPARATOR
Intervention: Single-day antibiotic prophylaxis
Number of subjects: 150
Study 18589558 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 5 mg capsules under fasting conditions
Number of subjects: 92
Study 18589558 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 5 mg capsules under fed conditions
Number of subjects: 92
Study 16188130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gendicine combined with radiotherapy (GTRT)
Number of subjects: 69
Study 16188130 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 69
Study 12240572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilamellar Tarsal Rotation (BTR)
Number of subjects: 153
Study 12240572 — intervention group
Group type: COMPARATOR
Intervention: Tarsotomy (TTR)
Number of subjects: 153
Study 12240572 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BTR and TTR
Number of subjects: 153
Study 12240572 — intervention group
Group type: EXPERIMENTAL
Intervention: BTR
Number of subjects: 153
Study 9681664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 16
Study 9681664 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 16
Study 8116134 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus estramustine phosphate (EMP), 2 x 280 mg/day
Number of subjects: 99
Study 8116134 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus flutamide, 3 x 250 mg/day
Number of subjects: 99
Study 3220007 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam 250 mg plus ampicillin 500 mg intravenously
Number of subjects: 10
Study 3220007 — intervention group
Group type: EXPERIMENTAL
Intervention: sultamicillin equivalent to sulbactam 294 mg plus ampicillin 440 mg orally
Number of subjects: 10
Study 3220007 — intervention group
Group type: COMPARATOR
Intervention: clavulanic acid 100 mg plus amoxycillin 500 mg intravenously
Number of subjects: 10
Study 3220007 — intervention group
Group type: COMPARATOR
Intervention: clavulanic acid 125 mg plus amoxycillin 500 mg orally
Number of subjects: 10
Study 31903588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 μg/kg 10 min before induction followed by continuous infusion of 0.5 μg/kg/h until 1h before end of surgery)
Number of subjects: 619
Study 31903588 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (volume-matched, same schedule as dexmedetomidine)
Number of subjects: 619
Study 31903588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 619
Study 31903588 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 619
Study 30315206 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP with TDF-FTC
Number of subjects: 0
Study 26821042 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% protein diet
Number of subjects: 0
Study 26821042 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein diet
Number of subjects: 0
Study 26821042 — intervention group
Group type: COMPARATOR
Intervention: 10% protein diet
Number of subjects: 0
Study 24529292 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (wet-granulation tablet)
Number of subjects: 60
Study 24529292 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (dry-granulation tablet)
Number of subjects: 60
Study 24529292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study 23682639 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 h)
Number of subjects: 27
Study 23682639 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (9 h)
Number of subjects: 27
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 20 μg estrogen
Number of subjects: 588
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 30 μg estrogen
Number of subjects: 588
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 35 μg estrogen
Number of subjects: 588
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 50 μg estrogen
Number of subjects: 588
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Women carrying the 1601GG genotype
Number of subjects: 588
Study 21737124 — intervention group
Group type: EXPERIMENTAL
Intervention: Women carrying the 1601GA genotype
Number of subjects: 588
Study 19251767 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cues in antismoking advertisements (weak argument condition)
Number of subjects: 96
Study 19251767 — intervention group
Group type: COMPARATOR
Intervention: No cue in antismoking advertisements
Number of subjects: 96
Study 16728513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained knee extension at 2.5% MVC force for 1 h
Number of subjects: 41
Study 16728513 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of alternate muscle activity for RF-VL and RF-VM pairs
Number of subjects: 41
Study 16728513 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of alternate muscle activity for VL-VM pair
Number of subjects: 41
Study 16728513 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of alternate muscle activity with MVC force reduction
Number of subjects: 41
Study 15306618 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling program plus educational program
Number of subjects: 17
Study 15306618 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling program
Number of subjects: 17
Study 15306618 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supply program plus educational program
Number of subjects: 17
Study 15306618 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 17
Study 15306618 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 11507356 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (FAT group; n = 60)
Number of subjects: 120
Study 11507356 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (OAT group; n = 60)
Number of subjects: 120
Study 11507356 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (FAT group)
Number of subjects: 120